Ireland in line for 3.3m additional Pfizer doses as EU doubles vaccine deal

EMA approves sixth dose from BioNTech vaccine as Astra Zeneca set to submit application to EU

January 7th, 2021: Curragh Lawn Nursing Home became the first facility in Co Kildare to receive the Covid-19 vaccination when 37 residents and 52 members of staff received the first dose of the Pfizer Bion Tech vaccine. Video: Bryan O'Brien


Ireland is in line for an additional 3.3 million vaccines after the European Union reached a deal with Pfizer and BioNTech for 300 million more doses of their Covid-19 vaccine.

The agreement doubles the amount of doses from these producers, the head of the European Commission Ursula von der Leyen said on Friday.

“The European Commission today proposed to the EU member states to purchase an additional 200 million doses of the Covid-19 vaccine produced by BioNTech and Pfizer, with the option to acquire another 100 million doses,” it said in a statement.

“This would enable the EU to purchase up to 600 million doses of this vaccine, which is already being used across the EU,” the statement said.

Ms Von der Leyen said 75 million of the additional doses would be delivered in the second quarter of this year.

Also on Friday Europe’s medicines regulator gave the go ahead for an extra sixth dose to be extracted from Pfizer-BioNTech Covid-19 vaccine vials, increasing the number of available shots at a time when supplies are short.

Speaking to RTE’s Today with Claire Byrne, the chair of the State’s Covid-19 vaccination taskforce Prof Brian MacCraith said the State should receive an additional 3.3 million vaccines “on top of what is coming already”.

He said that if other brands of vaccines become available “big numbers” of people will have been vaccinated by the summer.

At present the only thing he was certain of was that 40,000 doses per week would arrive, he told RTÉ radio’s Claire Byrne show. The pace of the vaccination programme was dependent on availability of the vaccine, he added.

“We’re assured of just over 40,000 vaccine doses arriving from Pfizer per week. That’s the only thing we’re absolutely certain of. Just multiply the number of weeks left in the quarter and that’s what the commitment is,” he said.

It comes as the European Medicines Agency said it has received more data from Astra Zeneca to submit a conditional marketing application for its Covid-19 vaccine, developed with Oxford next week with a possible conclusionby the end of January. This vaccine would be easier to roll out because it can be stored in fridges.

Effective against mutations

Meanwhile, a new laboratory study has shown that the Pfizer and BioNTech Covid-19 vaccine appeared to work against a key mutation in the highly transmissible new variants of the coronavirus discovered in Britain and South Africa.

The study by Pfizer and scientists from the University of Texas Medical Branch, which has not yet been peer-reviewed, indicated the vaccine was effective in neutralizing virus with the so-called N501Y mutation of the spike protein.

The mutation could be responsible for greater transmissibility and there had been concern it could also make the virus escape antibody neutralization elicited by the vaccine, said Phil Dormitzer, one of Pfizer’s top viral vaccine scientists.

The first results of tests on the variants offer a glimmer of hope while more studies are carried out as Britain and other countries try to tame the more infectious variants which authorities believe are driving a surge in infections that could overwhelm healthcare systems.

The Pfizer-BioNTech study was conducted on blood taken from people who had been given the vaccine. Its findings are limited because it does not look at the full set of mutations found in either of the new variants of the rapidly spreading virus.

Mr Dormitzer said it was encouraging that the vaccine appears effective against the mutation, as well as 15 other mutations the company has previously tested against.

“So we’ve now tested 16 different mutations, and none of them have really had any significant impact. That’s the good news,” he said. “That doesn’t mean that the 17th won’t.”

Mr Dormitzer said another mutation found in the South African variant, called the E484K mutation, was also concerning.

The researchers plan to run similar tests to establish whether the vaccine is effective against other mutations found in the British and South African variants and hope to have more data within weeks.

The variants are said by scientists to be more transmissible than previously dominant ones, but they are not thought to cause more serious illness.

Scientists said the results of the study would help calm concerns that people will not be protected by vaccines being given to millions of people around the world in the fight against the pandemic, which has killed more than 1.8 million people and roiled economies.

But they cautioned that more clinical tests and data are still needed to come to a definitive conclusion.

“This is good news, mainly because it is not bad news,” said Stephen Evans, professor of pharmacoepidemiology, London School of Hygiene & Tropical Medicine.

“So, yes this is good news, but it does not yet give us total confidence that the Pfizer (or other) vaccines will definitely give protection.”


AstraZeneca, Moderna and CureVac are also testing whether their shots work against the fast-spreading variants. They have said they expect them to be effective, but the timing of those studies are not known.

A senior British lawmaker expressed concerns in an interview on Friday that Covid-19 vaccines might not work properly against the South African variant. He was not responding to questions about Friday’s data.

The Pfizer/BioNTech vaccine and the one from Moderna, which use synthetic messenger RNA technology, can be quickly tweaked to address new mutations of a virus if necessary. Scientists have suggested the changes could be made in as little as six weeks.

The variant is not the first of the pandemic to emerge and Eleanor Riley, professor of immunology and infectious disease at the University of Edinburgh, said these types of study will be needed as they appear.

“It may be necessary to tweak the vaccine over time,” she said.

– Reuters